CLCC awarded £1m NIHR funding to address threatened miscarriage

Pioneering technology to address threatened miscarriage secures £1 million funding and moves towards clinical trials

Scientists developing a pioneering device designed to address threatened miscarriage have secured £1 million in NIHR funding to begin clinical trials

Designed to deliver vital doses of progesterone, the Callavid® device stands to help over 150,000 women each year in the UK

If approved, it would become the world’s first drug-device combination product to treat threatened miscarriage

See full press release here.

We use cookies to enhance your website experience. We use necessary cookies to ensure our website functions properly and to keep it secure. These always need to be on. By clicking “Accept cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyse site usage, and assist in our marketing efforts. Please view our privacy policy for further details.